MENS NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Jyong Biotech Ltd. Ordinary Shares · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 2.15 USD
-8.9% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -2.8% below the Trend Line and sits at 1.1% of its 52-week range. The latest completed week returned -8.9%, after a -3.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is mixed with 27/100 conviction, while the latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 25 out of 100
Latest Close 2.15 USD 31 Jul 2026
1W Return -8.9% latest completed week
4W Return -3.2% short-term follow-through
12W Return 4.9% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -8.9% Latest completed week; four-week move -3.2%. Indicator stack 0/59 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Mixed 27/100 conviction; expected move 18.2%. News sentiment 52/100 47 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -2.8% below the Trend Line and sits at 1.1% of its 52-week range. The latest completed week returned -8.9%, after a -3.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0712-week average 0.05

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.07Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -3.2% over four weeks, 4.9% over 12 weeks, and -88.8% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-8.9%
4W-3.2%
12W4.9%
26W-8.9%
52W-88.8%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.46Latest activity-pressure read.
Pressure change11.3%Four-week change in activity pressure.
Leadership-89.91Latest relative-leadership reading.
RS change0.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 58% Model confidence 47%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength55/100Blend of value, momentum, and quality. Underlying universe rank 46; rank 1 is best.
Value51/100Relative valuation strength. Underlying universe rank 50; rank 1 is best.
Quality50/100Profitability and accounting quality. Underlying universe rank 51; rank 1 is best.
Momentum52/100Medium-term price momentum. Underlying universe rank 49; rank 1 is best.
Growth52/100Revenue and earnings growth. Underlying universe rank 49; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-1.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-9.9%
Net share repurchases relative to market value.
Shareholder yield
-9.9%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-6.6x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

MENS shows mixed options pressure with a 27/100 conviction score, put-call volume ratio of n/a, expected move of 18.2%, and Sharemaestro trend signal inactive.

Conviction27/100
Expected move18.2%
Put/call volume
Pressure-12
Speculation0
Volatility93
Trend agreement49
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment52/100

Weighted news tone is neutral across 47 relevant articles.

10 positive · 30 neutral · 7 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move18.2%Nearest-chain priced movement where available.
52-week drawdown-96.8%Distance below the 52-week high.
13-week volatility10.9%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+29.7%Week of 20 Feb.
Worst week-21.8%Week of 12 Jun.
Latest week-8.9%Week of 31 Jul.

Shape of recent returns

Strong gains8
Modest gains5
Flat weeks0
Modest losses4
Sharp losses9
Recent vol10.9%13-week weekly-return volatility.
Base vol25.9%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew14.8% / -14.0%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape22/100

Trend, activity pressure, participation, and risk combine to a 22/100 tape read.

 Indicator analysis30/100

Latest 12-week confirmation: trend 0/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.07; No reversal markers Factors51/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 86; Small Cap Core rank 53 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options43/100

MENS shows mixed options pressure with a 27/100 conviction score, put-call volume ratio of n/a, expected move of 18.2%, and Sharemaestro trend signal inactive.

Mixed · Options-market disagreement · Expected move 18.2% Sentiment52/100

Weighted news tone is neutral across 47 relevant articles.

Jyong Biotech Ltd (MENS) Earnings Forecast: Future EPS & Revenue Growth Estimates Insiders50/100

No recent insider transaction evidence is stored.

 Earnings11d

Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20262.15 USD-8.9%2.21 USD17.66 USD0.46-89.91285.6KOff
24 Jul 20262.36 USD4.4%2.25 USD17.93 USD0.53-89.08338.6KOff
17 Jul 20262.26 USD2.3%2.28 USD18.20 USD0.54-89.84260.2KOff
10 Jul 20262.21 USD-0.5%2.31 USD18.49 USD0.47-90.57310.0KOff
3 Jul 20262.22 USD18.1%3.07 USD18.78 USD0.41-90.44552.0KOff
26 Jun 20261.88 USD20.5%3.97 USD19.09 USD0.34-91.891.1MOff
19 Jun 20261.56 USD-1.3%4.81 USD19.41 USD0.29-93.63762.7KOff
12 Jun 20261.58 USD-21.8%5.78 USD19.76 USD0.36-93.42787.5KOff
5 Jun 20262.02 USD-8.2%7.00 USD20.11 USD0.38-367.2KOff
29 May 20262.20 USD2.3%8.23 USD20.47 USD0.33-166.3KOff
22 May 20262.15 USD7.0%9.65 USD20.85 USD0.28-249.9KOff
15 May 20262.01 USD-2.0%11.60 USD21.24 USD0.22-219.0KOff
8 May 20262.05 USD-8.9%13.50 USD21.65 USD0.17-365.1KOff
1 May 20262.25 USD2.7%15.28 USD22.07 USD0.14-247.1KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.